Answers are grounded in this paper and cite their sources.
Phase 2 study evaluates isatuximab monotherapy's effectiveness in multiple myeloma patients, suggesting potential for treatment.
The use of novel therapies, such as immunomodulatory drugs (IMiDs), proteasome inhibitors (PIs), and monoclonal antibodies (mAbs; ie, isatuximab, daratumumab, elotuzumab), has significantly improved the outcomes of multiple myeloma (MM) patients. However, MM remains largely incurable, with the majority of patients becoming refractory to available therapies and eventually relapsing.
No takes yet. Share an insight, caveat, or question.
Mıkhael et al. (2021) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: